Combination therapies are a cost-effective alternative when treating visceral leishmaniasis

Combination therapies are a cost-effective alternative when treating visceral leishmaniasis

Visceral leishmaniasis is the second-deadliest parasitic disease after malaria. Each year, thousands fall victim among poor and marginalised populations in low-income countries. Filip Meheus is the first to detail the economic aspects of the disease in India, Nepal and Sudan. On Monday 16 September, Meheus will receive a PhD title at the University of Nijmegen for his research at the Institute of Tropical Medicine (ITM) in Antwerp.

Visceral leishmaniasis has become harder to control, because current treatments increasingly fail (like in Nepal with resistance to the drug miltefosine).

Meheus shows that combination therapies (the use of multiple drugs) is a cost-effective alternative to the current first-line treatments. This is mainly due to the shorter duration of treatment and the lower cost of the drugs used for combination therapies.

Combination therapies would also alleviate the enormous the disease causes in families and relieve the workload in hospitals. However, additional efforts are needed to further drop prices of some drugs (like liposomal amphotericin B) and diagnose and treat patients more quickly.

"This disease wrecks patients twice, both physically and financially. The study results offer some tools to assist them better, even where the needs are huge and the means limited," said Meheus.

The article is titled "The economic analysis of control."

More information: www.itg.be/internet/dl/Economi… trol-FilipMeheus.pdf

add to favorites email to friend print save as pdf

Related Stories

Kala-azar treatment failing in Nepal

Mar 01, 2013

In a recent study, scientists have concluded that the cure rates of Miltefosine, the only oral drug for visceral leishmaniasis available, have significantly decreased. Miltefosine was introduced in the Indian subcontinent ...

Old drug shows new promise to treat leishmaniasis

Feb 02, 2012

(Medical Xpress) -- A study published yesterday shows that a drug called fexinidazole could potentially be used to treat visceral leishmaniasis, a parasitic disease that kills 50 000 to 60 000 people ...

Genetics discovery to help fight 'black fever'

Jan 08, 2013

Scientists—including a geneticist at The University of Western Australia—are a step closer to developing a vaccine against a fatally infectious parasite carried in the bite of sandflies.

Recommended for you

Nigeria confirms two new Ebola cases (Update)

1 hour ago

Two new cases of Ebola have emerged in Nigeria and, in an alarming development, they are outside the group of caregivers who treated an airline passenger who arrived with Ebola and died, Health Minister Onyebuchi ...

Senegal closes border as UN warns on Ebola flare-up

6 hours ago

Senegal has become the latest country to seal its border with a west African neighbour to ward off the deadly Ebola virus, as the new UN pointman on the epidemic said preparations must be made for a possible flare-up of the ...

Climate change could see dengue fever come to Europe

6 hours ago

Dengue fever could make headway in popular European holiday destinations if climate change continues on its predicted trajectory, according to research published in open access journal BMC Public Health.

American Ebola doc: 'I am thrilled to be alive'

14 hours ago

Calling it a "miraculous day," an American doctor infected with Ebola left his isolation unit and warmly hugged his doctors and nurses on Thursday, showing the world that he poses no public health threat ...

User comments